AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02814448 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 standard cryotherapy
Description: Standard therapy using carbon dioxide for freezing of tissue
Study NCT03756467 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Girl Empower Program
Description: Girl Empower (GE) encourages adolescent girls living in rural areas of Nimba County, Liberia to partake in weekly mentored community-based workshops on life skills, selfcare, and financial literacy.
Study NCT04144738 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FIT test
Description: Stool samples will be collected by the subject for the FIT test.
Study NCT02916043 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiovascular surgery with cardiopulmonary bypass
Description: Patients who underwent cardiovascular surgery including valve replacement or thoracic aortic surgery with cardiopulmonary bypass
Study NCT03993730 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ICD
Description: Insertion of ICD in patients with LVEF \<45% and LGE on CMR.
Study NCT03993730 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ILR
Description: Insertion of ILR in patients with LVEF \<45% and LGE on CMR.
Study NCT01088802 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks)
Study NCT02814448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermocoagulator
Description: The use of heat produced by high-frequency electric current to bring about local destruction of tissues
Study NCT05278767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Mobile Education and Counselling
Description: The patients in the experimental group received e-mobile training and consultancy services with the mobile application developed specifically for bariatric surgery that started before the operation and lasted for 3 months.
Study NCT04396678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP standard of care+behavioral intervention
Description: The intervention includes three main components: 1) group PrEP engagement sessions, which include four educational sessions that situate PrEP in a broader framework of access and barriers to care, provider/patient communication, sexual health, HIV/STI education, harm reduction around drug use, stigma, risk compensation and safe sex, and health/science literacy; 2) peer navigation, which aims to help women navigate healthcare engagement with the SPARC nurse practitioner and other providers; and 3) an mHealth component, consisting of a two-way text messaging system through which women will receive automated daily messages and weekly messages requesting adherence reports.
Study NCT01142349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyles A
Description: Six weekly group sessions that last about 90-120 minutes presenting cognitive behavioral therapy for pain and insomnia
Study NCT01142349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyles B
Description: Six weekly group sessions that last about 90-120 minutes presenting cognitive behavioral therapy for pain.
Study NCT01142349 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyles C
Description: Six weekly group sessions that last about 90-120 minutes presenting osteoarthritis education.
Study NCT02438332 — intervention group
Intervention type: DEVICE
Intervention: Smooth NATRELLE® INSPIRA® TruForrm® 1 Breast Implants
Description: Surgical implant
Study NCT02969694 — intervention group
Intervention type: OTHER
Intervention: G-STAT questionnaire
Description: Patients will have a consultation with an addiction specialist physician. During the consultation, the physician ask the patient about these sexual practice and the use of psychostimulants. The patient will answer to the G-STAT questionnaire. This questionnaire allows the physician to perform an initial assessment of the patient's sexual addiction.~The entire consultation takes place in the usual practice of consultations for this addiction.
Study NCT00243685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Assay
Description: Chemotherapy
Study NCT02438332 — intervention group
Intervention type: DEVICE
Intervention: Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants
Description: surgical implant
Study NCT01088802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered weekly for the first 3 weeks and the last 3 weeks of radiation. Patients will not receive chemotherapy during week 4 of treatment.
Study NCT01088802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered weekly during the 7 weeks of radiation. Carboplatin may be given as a substitution for cisplatin when cisplatin-related toxicities occur or when patients present with greater than grade 2 sensory or motor neuropathy, greater than 2 hearing loss, or less than 60 ml/min creatinine clearance.
Study NCT02438332 — intervention group
Intervention type: DEVICE
Intervention: Smooth NATRELLE® INSPIRA® TruForrm® 2 Breast Implants
Description: surgical implant
Study NCT01511198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Injected subcutaneously once daily
Study NCT01511198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 1000 mg twice daily, administered orally
Study NCT00243685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mick Assay
Description: Chemotherapy doctor determined from results
Study NCT00462618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Study NCT00351819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AndroGel
Description: 5g gel, applied once daily to the upper arms, upper back or shoulders.
Study NCT00351819 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5g gel, applied once daily to the upper arms, upper back or shoulders.
Study NCT00992524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Oral solution dose will be 20mcg/hour (misoprostol) or 10ml/hour (placebo) in the first six hours with an increase of 20mcg/hour (10ml/hour) of misoprostol or placebo each six hours if labour does not start, until the maximum dose of 80mcg/hour or 40ml/hour in the first 24 hours.
Study NCT06314997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab (EGFR inhibitors)
Description: Chemotherapy treatment includes anti-EGFR biologics such as cetuximab or panitumumab, antiangiogenic drugs such as bevacizumab or aflibercept. The indication to treat depends from the presence of CTCs analysed for Ras mutation and HER2 expression
Study NCT04410081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-lazertinib
Description: A single oral dose of 14C-lazertinib will be administered.
Study NCT03101527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation
Description: Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g docosahexaenoic daily for the duration of the study
Study NCT00562016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMPLELLA LP 2.5
Description: Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5 L/min.
Study NCT00992524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Vaginal tablets will have 25mcg of misoprostol or placebo.
Study NCT00562016 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IABP Intra-aortic balloon pump
Description: IABP uses counterpulsation to provide 0.2L/min coronary flow
Study NCT02866734 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free screening group
Description: The intervention provide Diabetic Retinopathy screening without charging a fee.
Study NCT04295135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Pain OneSheet
Description: The Chronic Pain OneSheet (OneSheet) is an EHR decision support tool that uses behavioral economics to increase adoption of chronic pain guideline recommendations. OneSheet works by aggregating and structuring information that is already collected, that PCPs often need while caring for patients with chronic pain conditions. By aggregating and structuring this information in a more convenient manner, the goal of OneSheet is to make the information that is important in clinical decision making more readily available, and to reduce the amount of time that PCPs need to spend locating this information.
Study NCT00134043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT00596037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone - LB03002
Study NCT04644874 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Geriatric 8
Description: The G8 is an eight-item screening tool, developed for older cancer patients. The G8 score ranges from 0 (heavily impaired) to 17 (not at all impaired), with a cut-off for potential frailty of ≤14.
Study NCT04644874 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: modified Geriatric 8
Description: The mG8 is a modified version of the Geriatric 8 screening tool, consisting of 6-items. The mG8 score ranges from 0 (not at all impaired) to 35 (heavily impaired), with a cut-off for potential frailty at ≥6.
Study NCT04644874 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 30 second chair stand test
Description: Repetitions within 30 seconds
Study NCT04644874 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Handgrip Strength Test
Description: Measured in kilograms
Study NCT04236726 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: HRQoL questionnaires
Study NCT01072955 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bovine Heparin
Description: 5.000UI/mL bottle with 5mL
Study NCT01072955 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Porcine heparin
Description: 5000 USP Heparin Units / mL vial with 10 mL vial
Study NCT02866734 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pay screening group ($150)
Description: The intervention is charging HK$150 for the Diabetic Retinopathy screening.
Study NCT02866734 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pay screening group ($300)
Description: The intervention is charging HK$300 for the Diabetic Retinopathy screening.
Study NCT05521139 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: drug sensitivity results
Description: drug sensitivity results including the carbapenem-resistant Klebsiella pneumoniae and carbapenem-sensitive Klebsiella pneumoniae
Study NCT03760354 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 0.9%, 100ml per day as a single slow intravenous administration over 60 minutes for a total treatment duration of 5 days
Study NCT04386772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVE with coils plus TAGM
Description: PVE with TAGM distally and coils proximally and subsequent scheduled major hepatectomy. Sequential transcatheter arterial chemoembolization and PVE for patients with HCC. Selective biliary drainage on future liver remnant (FLR) side for patients with pCCA when obstructive jaundice is present.
Study NCT00805753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACTH
Description: comparison of different dosages of drug
Study NCT02056392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Volunteers will receive 75 mg selumetinib oral dose (Treatment A)
Study NCT02056392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Volunteers will receive 400 mg Moxifloxacin oral dose (Treatment B)
Study NCT02056392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: selumetinib placebo
Description: Volunteers will receive selumetinib placebo oral dose (Treatment C)
Study NCT03416244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg IV fixed dose every two weeks
Study NCT03416244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1mg/kg IV every six weeks (starting in week 7 after safety assessment)
Study NCT04386772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVE with multiple coils
Description: Procedure: PVE with multiple coils PVE with multiple coils proximally and distally and subsequent scheduled major hepatectomy. Sequential transcatheter arterial chemoembolization and PVE for patients with HCC. Selective biliary drainage on FLR side for patients with pCCA when obstructive jaundice is present.
Study NCT00000936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hOKT3
Description: Administered both during and after transplantation in IV form. Dosage determined by individual weight and given for a maximum of 14 days.
Study NCT02408068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone used to suppress endogenous cortisol secretion
Study NCT04144738 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Subjects will undergo a screening colonoscopy.
Study NCT03111004 — intervention group
Intervention type: OTHER
Intervention: New Care
Description: All settings that are in any way relevant to the provision of health and social care are integrated, including: out-of-hospital (community) services as well as hospitals, GPs' offices, community nurses, and any type of care practitioners, users' homes and volunteer service providers' offices
Study NCT03355248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone Acetaminophen
Description: Decrease in opioid prescribing for post-operative cesarean pain management
Study NCT03355248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxycodone Acetaminophen
Description: Decrease in opioid prescribing for post-operative cesarean pain management
Study NCT00682175 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Pulmonary Artery pressure (PA), pulmonary capillary wedge pressure (PCWP), cardiac output (CO), and cardiac index (CI). This data will be collected after 24 ± 2 and 48 ± 2 hours of standard heart failure therapy
Study NCT03519399 — intervention group
Intervention type: DEVICE
Intervention: Monica AN24
Description: Monica AN24 will be used to record maternal and fetal ECGs. The Zephyr will be used to determine maternal lie.
Study NCT00358033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Study NCT00358033 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Study NCT00358033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Education
Study NCT00358033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Support
Study NCT00358033 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacologic case management
Description: Provided by clinical pharmacists
Study NCT00358033 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacologic case management
Description: Provided by clinical pharmacists
Study NCT04335630 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram, telemetry, echocardiogram, laboratory values
Description: Serial electrocardiograms, telemetry monitoring, echocardiographic assessment and serial laboratory testing will be used to identify differences among the two study groups.
Study NCT00572429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: l-carnitine
Description: 3 gram daily dose
Study NCT02408068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chronocort: fasted
Description: single dose of 20mg modified release hydrocortisone in the absence of food
Study NCT02408068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate release hydrocortisone: fasted
Description: single dose of 20mg immediate release hydrocortisone in the absence of food
Study NCT04207515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedures of wisdom tooth removal surgery under conscious sedation
Description: The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
Study NCT04207515 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedures of wisdom tooth removal surgery under local anesthesia
Description: The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
Study NCT02408068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chronocort: fed
Description: single dose of 20mg modified release hydrocortisone in the presence of food
Study NCT03929783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Digital Mammography
Description: Undergo CEM
Study NCT04733872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subjects drank 50 ml , 1 bottle a day for 8 week
Study NCT04733872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegetable and Berry Drink
Description: subjects drank 50 ml , 1 bottle a day for 8 week
Study NCT01328197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treovance Abdominal Aortic Stent-Graft with Navitel Delivery System
Description: Stent-graft implant
Study NCT02059018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COX-inhibitor
Description: Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
Study NCT04600687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo tablets
Description: Participants will take placebo tablets identical to the commercial versions of the two combination antiretroviral single tablet regimens of bictegravir/emtricitabine/tenofovir alanfenamide and dolutegravir/abacavir/lamivudine.
Study NCT03222219 — intervention group
Intervention type: PROCEDURE
Intervention: dental implant insertion
Description: the registration of the torque values is discriminant for the group assignment after dental implant insertion
Study NCT02059018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: Oral administration of tablet nitroglycerin 0,5mg 5 minutes before recordings of diameter changes of retinal vessels are initiated
Study NCT03030898 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: respiratory variation of the right internal jugular vein
Description: respiratory variation of the right internal jugular vein vs respiratory variation of superior and inferior cava vena
Study NCT04365686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketofol as induction agent
Description: Patients who received propofol (1mg/kg) plus ketamine (0.5mg/kg) at the induction of general anesthesia
Study NCT02059018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COX-inhibitor + Nitroglycerin
Description: Combination of COX-inhibitor and nitroglycerin interventions.
Study NCT00462618 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cogntive behavioral therapy
Study NCT00461422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: sc injection of Ganirelix 0.25 mg per day
Study NCT00510484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase Delayed Release
Description: 24000 unit Capsule
Study NCT00510484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo
Study NCT02221947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bryostatin 1
Description: 25 μg/m2 bryostatin 1, single dose via intravenous infusion over 1 hour.
Study NCT01325181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verteporfin
Description: a 6mg/m2 infusion of verteporfin(Visudyne; Novartis)over 10 minutes followed by laser delivery
Study NCT01325181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Consecutive intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months
Study NCT03920176 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Computed tomography coronary angiography
Description: CTCA >64 detector row scanner